Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ranibizumab in Two Treat and Extend Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patient~* Patients with Type 1 or Type 2 diabetes mellitus (according to American Diabetes Association or World Health Organization \[WHO\] guidelines) with glycosylated hemoglobin (HbA1c) ≤ 12.0% at screening (Visit 1). Patients should be on diet, exercise, and/or pharmacological treatment for diabetes. Treatment for diabetes must have been stable for at least 3 month.~Ocular~* Patients with visual impairment due to DME in at least one eye who are eligible for laser treatment in the opinion of the investigator. If both eyes are eligible, the one with the worse visual acuity, as assessed at Visit 1, will be selected by the investigator as the study eye.~* BCVA ≥ 39 and ≤78 letters in the study eye and, inclusively, using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters (approximate Snellen equivalent of 20/32 to 20/160) at screening.~* Concomitant conditions in the study eye are only permitted if, in the opinion of the investigator, they do not prevent improvement of visual acuity on study treatment.~Exclusion Criteria:~Patient Compliance/ Administrative~* Pregnant or nursing (lactating) women.~Ocular medical history~* Active intraocular inflammation (grade trace or above) in either eye at enrollment.~* Any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) in either eye at the time of enrollment.~* History of uveitis in either eye at any time.~* Structural damage within 0.5 disc diameter of the center of the macular in the study eye likely to preclude improvement in visual acuity following the resolution of macular edema.~* Uncontrolled glaucoma in either eye at screening.~Prior Ocular treatments~* Panretinal laser photocoagulation in the study eye within 6 months prior to randomization.~* Focal/grid laser photocoagulation in the study eye within 3 months prior to randomization.~* Treatment with anti-angiogenic drugs in either eye.~Systemic conditions or treatments~* History of stroke within 6 months prior to enrollment.~* Renal failure requiring dialysis.~* Untreated diabetes mellitus.~* Blood pressure systolic \> 160 mmHg or diastolic \> 100 mmHg.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TE Ranibizumab 0.5 mg and Laser (Type: EXPERIMENTAL): On Day 1, all patients received an intravitreal injection with 0.5 mg ranibizumab and subsequently entered Phase A which comprised of monthly injections. Laser therapy was applied at Day 1. It could then be re-administered according to ETDRS criteria at any visit with 0.5 mg ranibizumab treatment if deemed necessary by the Treating Investigator with a minimal treatment interval between laser treatments of 3 months. Laser therapy was administered ≥ 30 minutes prior to the ranibizumab injection.
- TE Ranibizumab 0.5 mg alone (Type: EXPERIMENTAL): Patients received ranibizumab intravitreal injection therapy only.
- PRN Ranibizumab 0.5 mg (Type: ACTIVE_COMPARATOR): Patients received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).